Sienna Biopharm (SNNA) Stake Maintained by Partner Fund Management, L.P.
Partner Fund Management, L.P.
recently disclosed that they own a 9.2% stake in Sienna Biopharm (NASDAQ:SNNA) in a Form 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Monday, August 7th. The investor owns 1,881,472 shares of the stock valued at about $36,519,372. The reporting parties listed on the disclosure included Partner Fund Management, LP, Partner Fund Management GP, LLC, Partner Investment Management, LP, Partner Investment Management GP, LLC, Brian D Grossman and Christopher M James. The disclosure is available through EDGAR at this link.
Partner Fund Management, L.P.
provided the following explanation of their ownership:
Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Shares of Sienna Biopharm (NASDAQ:SNNA) traded up 2.92% during midday trading on Monday, hitting $19.41. The stock had a trading volume of 98,085 shares. Sienna Biopharm has a one year low of $18.50 and a one year high of $21.20.
COPYRIGHT VIOLATION WARNING: “Sienna Biopharm (SNNA) Stake Maintained by Partner Fund Management, L.P.” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/sienna-biopharm-snna-stake-maintained-by-partner-fund-management-l-p.html.
In related news, Director Keith R. Leonard bought 16,700 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was bought at an average price of $15.00 per share, with a total value of $250,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Richard D. Peterson bought 7,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was bought at an average cost of $15.00 per share, with a total value of $105,000.00. Following the transaction, the chief financial officer now directly owns 7,000 shares of the company’s stock, valued at $105,000. The disclosure for this purchase can be found here. Insiders bought 48,700 shares of company stock valued at $730,500 in the last ninety days.
About Sienna Biopharm
Sienna Biopharmaceuticals, Inc is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125.
Want to see what other hedge funds are holding SNNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sienna Biopharm (NASDAQ:SNNA).
Receive News & Ratings for Sienna Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.